AstraZeneca plc’s (NASDAQ:AZN) cancer drug, Imfinzi (durvalumab), in conjunction with standard chemotherapy, has now received endorsement from the U.S. authorities for treating certain severe forms of endometrial cancer. The U.S. Food and Drug Administration’s (FDA) approval is specifically for adults with primary, advanced, or recurrent endometrial cancer that shows mismatch repair deficiency (dMMR). The decision stems from the compelling evidence provided by the DUO-E Phase III trial, which has been documented in the Journal of Clinical Oncology. In the clinical study, patients treated with …